{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:24:43Z","timestamp":1787955883529,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s10238-019-00565-8","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T06:22:05Z","timestamp":1560838925000},"page":"281-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8019-4965","authenticated-orcid":false,"given":"Maria Giulia","family":"Tinti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Molinaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Migliore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"De Cata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"565_CR1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1191\/0961203303lu394oa","volume":"12","author":"R Asherson","year":"2003","unstructured":"Asherson R, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530\u20134.","journal-title":"Lupus"},{"key":"565_CR2","doi-asserted-by":"publisher","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","volume":"4","author":"K Schreiber","year":"2018","unstructured":"Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103.","journal-title":"Nat Rev Dis Primers"},{"key":"565_CR3","first-page":"508","volume":"19","author":"RA Asherson","year":"1992","unstructured":"Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19:508\u201312.","journal-title":"J Rheumatol"},{"key":"565_CR4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.23736\/S0031-0808.17.03324-9","volume":"59","author":"G Espinosa","year":"2017","unstructured":"Espinosa G, Rodr\u00edguez-Pint\u00f3 I, Cervera R. Catastrophic antiphospholipid syndrome: an update. Panminerva Med. 2017;59:254\u201368.","journal-title":"Panminerva Med"},{"key":"565_CR5","first-page":"18863","volume":"18","author":"R Cervera","year":"2009","unstructured":"Cervera R, Tincani A. European Working Party on systemic lupus erythematosus and European Forum on Antiphospholipid Antibodies: two networks promoting European research on autoimmunity. Lupus. 2009;18:18863\u20138.","journal-title":"Lupus"},{"key":"565_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","volume":"92","author":"R Cervera","year":"2018","unstructured":"Cervera R, Rodriguez-Pinto I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun. 2018;92:1\u201311.","journal-title":"J Autoimmun"},{"key":"565_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/art.10187","volume":"46","author":"R Cervera","year":"2002","unstructured":"Cervera R, Piette J-C, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019\u201327.","journal-title":"Arthritis Rheum"},{"key":"565_CR8","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/ard.2004.025759","volume":"64","author":"R Cervera","year":"2005","unstructured":"Cervera R, Font J, G\u00f3mez-Puerta J, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205\u20139.","journal-title":"Ann Rheum Dis"},{"key":"565_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.autrev.2014.03.002","volume":"13","author":"R Cervera","year":"2014","unstructured":"Cervera R, Rodr\u00edguez-Pint\u00f3 I, Colafrancesco S, et al. 14th International congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun Rev. 2014;13:699\u2013707.","journal-title":"Autoimmun Rev"},{"key":"565_CR10","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","volume":"57","author":"I Rodr\u00edguez-Pint\u00f3","year":"2018","unstructured":"Rodr\u00edguez-Pint\u00f3 I, Espinosa G, Erkan D, Shoenfeld Y, Cervera R, CAPS Registry Project Group. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology. 2018;57:1264\u201370.","journal-title":"Rheumatology"},{"key":"565_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.autrev.2010.08.005","volume":"10","author":"D Erkan","year":"2010","unstructured":"Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010;10:74\u20139.","journal-title":"Autoimmun Rev"},{"key":"565_CR12","first-page":"346","volume":"34","author":"UD Bayraktar","year":"2007","unstructured":"Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R, Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol. 2007;34:346\u201352.","journal-title":"J Rheumatol"},{"key":"565_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.autrev.2011.04.031","volume":"10","author":"G Espinosa","year":"2011","unstructured":"Espinosa G, Berman H, Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev. 2011;10:664\u20138.","journal-title":"Autoimmun Rev"},{"key":"565_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.semarthrit.2007.08.001","volume":"37","author":"RA Asherson","year":"2008","unstructured":"Asherson RA, Espinosa G, Menahem S, et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum. 2008;37:366\u201372.","journal-title":"Semin Arthritis Rheum"},{"key":"565_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.semarthrit.2012.05.005","volume":"42","author":"G Espinosa","year":"2013","unstructured":"Espinosa G, Rodr\u00edguez-Pint\u00f3 I, Gomez-Puerta JA, Pons-Estel G, Cervera R. Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum. 2013;42:417\u201323.","journal-title":"Semin Arthritis Rheum"},{"key":"565_CR16","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/art.34440","volume":"64","author":"I Shapira","year":"2012","unstructured":"Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64:2719\u201323.","journal-title":"Arthritis Rheum"},{"key":"565_CR17","first-page":"1","volume":"5","author":"D Erkan","year":"2016","unstructured":"Erkan D, Salmon JE. The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk J Haematol. 2016;5:1\u20137.","journal-title":"Turk J Haematol"},{"key":"565_CR18","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/rheumatology\/kew040","volume":"55","author":"A Barratt-Due","year":"2016","unstructured":"Barratt-Due A, Fl\u00f8isand Y, Orrem HL, et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology. 2016;55:1337\u20139.","journal-title":"Rheumatology"},{"key":"565_CR19","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","volume":"93","author":"A Kronbichler","year":"2014","unstructured":"Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine. 2014;93:e143.","journal-title":"Medicine"},{"key":"565_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.11.005","author":"N Kello","year":"2018","unstructured":"Kello N, LE Khoury, Marder G, Furie R, Zapantis E, Horowitz DL. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature. Semin Arthritis Rheum. 2018. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.11.005 .","journal-title":"Semin Arthritis Rheum"},{"key":"565_CR21","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1056\/NEJMc0910965","volume":"362","author":"BE Lonze","year":"2010","unstructured":"Lonze BE, Singer AL, Montgomery R. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362:1744\u20135.","journal-title":"N Engl J Med"},{"key":"565_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/ajt.12540","volume":"14","author":"BE Lonze","year":"2014","unstructured":"Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14:459\u201365.","journal-title":"Am J Transplant"},{"key":"565_CR23","first-page":"704371","volume":"2014","author":"M Strakhan","year":"2014","unstructured":"Strakhan M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrafei T. 36-Year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014;2014:704371.","journal-title":"Case Rep Hematol"},{"key":"565_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/RHU.0000000000000290","volume":"6","author":"TA Zikos","year":"2015","unstructured":"Zikos TA, Sokolove J, Ahuja N, Berube C. Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol. 2015;6:311\u20133.","journal-title":"J Clin Rheumatol"},{"key":"565_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/rheumatology\/kev371","volume":"55","author":"S Wig","year":"2016","unstructured":"Wig S, Chan M, Thachil J, Bruce I, Barnes T. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology. 2016;55:382\u20134.","journal-title":"Rheumatology"},{"key":"565_CR26","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1093\/rheumatology\/key228","volume":"57","author":"M Guillot","year":"2018","unstructured":"Guillot M, Rafat C, Buob D, et al. Eculizumab for catastrophic antiphospholipid syndrome\u2014a case report and literature review. Rheumatology. 2018;57:2055\u20137.","journal-title":"Rheumatology"},{"key":"565_CR27","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3389\/fimmu.2018.01388","volume":"9","author":"F Tedesco","year":"2018","unstructured":"Tedesco F, Borghi MO, Gerosa M, et al. Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications. Front Immunol. 2018;9:1388.","journal-title":"Front Immunol"},{"key":"565_CR28","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/art.21157","volume":"52","author":"SS Pierangeli","year":"2005","unstructured":"Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005;52:2120\u20134.","journal-title":"Arthritis Rheum"},{"key":"565_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajog.2006.10.879","volume":"196","author":"JM Shamonki","year":"2007","unstructured":"Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol. 2007;196:1\u20135.","journal-title":"Am J Obstet Gynecol"},{"key":"565_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.berh.2016.07.004","volume":"30","author":"I Rodriguez-Pint\u00f3","year":"2016","unstructured":"Rodriguez-Pint\u00f3 I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: the current management approach. Best Pract Res Clin Rheumatol. 2016;30:239\u201349.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"565_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000492033","volume":"48","author":"SR Olson","year":"2018","unstructured":"Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG. When to stop eculizumab in complement-mediated thrombotic microangiopathies. Am J Nephrol. 2018;48:96\u2013107.","journal-title":"Am J Nephrol"},{"key":"565_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","volume":"130","author":"SA Merrill","year":"2017","unstructured":"Merrill SA, Brittingham ZD, Yuan X, Moliterno AR, Sperati CJ, Brodsky RA. Eculizumab cessation in atypical hemolytic uremic syndrome. Blood. 2017;130:368\u201372.","journal-title":"Blood"},{"key":"565_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","volume":"67","author":"CM Nester","year":"2015","unstructured":"Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67:31\u201342.","journal-title":"Mol Immunol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-019-00565-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-019-00565-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-019-00565-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:21:48Z","timestamp":1663719708000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-019-00565-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1007\/s10238-019-00565-8","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]},"assertion":[{"value":"2 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from our patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}